A Phase 1 Dose-Escalation Study of LY2495655, an Anti-Myostatin Monoclonal Antibody, in Patients With Advanced Cancer
Phase of Trial: Phase I
Latest Information Update: 15 Feb 2016
At a glance
- Drugs Landogrozumab (Primary)
- Indications Breast cancer; Cancer; Prostate cancer
- Focus Adverse reactions
- Sponsors Eli Lilly
- 08 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 19 Oct 2015 Planned End Date changed from 1 Jul 2015 to 1 Jan 2016 as per ClinicalTrials.gov record.
- 05 Jun 2015 Planned End Date changed from 1 Jan 2014 to 1 Jul 2015 as reported by ClinicalTrials.gov record.